FDA Approval Of PRP Program In 2025 Will Open Significant Revenue Stream

Key Takeaways

• Growth in the porcine division and strategic partnerships in China are expected to enhance Genus's revenue and earnings.
  
• Expansion in the bovine segment through acquisitions and programs like VAP is projected to improve profit margins and financial stability.
  
• Genus faces challenges from softening pig prices in China, dairy market contraction, FX headwinds, and regulatory delays impacting profitability and growth.

Catalysts

Operates as an animal genetics company in North America, Latin America, the United Kingdom, rest of Europe, the Middle East, Russia, Africa, and Asia.

• Genus has achieved a 13% increase in operating profit in regions excluding China, and growth in the porcine division is expected to continue with the stabilization of growth in China due to signing royalty contracts with major producers. This should positively impact revenue and earnings.
  
• The commercialization of the PRP program, with expected FDA approval in 2025, represents a significant future revenue stream, potentially boosting revenue and net margins by introducing innovative products to the market.
  
• The Value Acceleration Program (VAP) in the bovine segment is expected to deliver a £21 million run rate benefit by fiscal year-end, improving margins, return on capital, and earnings through better inventory management and operational efficiencies.
  
• Genus's acquisition of full ownership in the ABS De Novo joint venture allows for greater control over genetic resources, potentially leading to stronger genetic offerings and improved profit margins in the bovine segment, positively impacting earnings and cash generation.
  
• Strong cash flow generation and a focus on managing working capital have enabled Genus to return to positive free cash flow, covering dividend payments and reducing net debt, which should enhance financial stability and potentially increase shareholder value in the future.

Genus Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Genus's revenue will grow by 3.0% annually over the next 3 years.
• Analysts assume that profit margins will increase from 7.1% today to 9.4% in 3 years time.
• Analysts expect earnings to reach £69.3 million (and earnings per share of £1.04) by about May 2029, up from £47.5 million today. However, there is some disagreement amongst the analysts with the more bearish ones expecting earnings as low as £56.6 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 37.6x on those 2029 earnings, up from 33.8x today. This future PE is greater than the current PE for the GB Biotechs industry at 19.3x.
• Analysts expect the number of shares outstanding to grow by 0.27% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.68%, as per the Simply Wall St company report.

Risks

• The softening pig prices in China could negatively impact porcine revenues and operating profit, given China's significance to the market and the variability in royalty revenue stream ramp-up time. This may affect Genus's revenue and profit margin stability.
  
• Continued challenges in the China dairy market, with evidence of contraction and recent import restrictions on US bovine semen, could adversely affect ABS China's profitability and revenue growth.
  
• Latin America's demand for beef genetics remains weak, with ABS Latin America suffering significantly from currency translation impacts. This could impact overall profitability and revenue growth in the region.
  
• The company's exposure to foreign exchange rate fluctuations, especially with the weakening of currencies in Latin America against the strengthening sterling, indicates a potential £8-9 million FX headwind. This affects profit before tax and earnings.
  
• Potential delays or uncertainties in FDA approval of the PRP and regulatory processes in other countries could postpone revenue benefits from this R&D commercialization prospect and impact growth expectations.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of £31.28 for Genus based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of £37.0, and the most bearish reporting a price target of just £25.5.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be £735.0 million, earnings will come to £69.3 million, and it would be trading on a PE ratio of 37.6x, assuming you use a discount rate of 7.7%.
• Given the current share price of £24.02, the analyst price target of £31.28 is 23.2% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.